Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gottlieb Becomes US FDA Commissioner With Immediate Issues Pending

Executive Summary

Senate confirmation includes fewest supporting votes for any candidate ever as agency tackles budget, user fees and other issues.

You may also be interested in...



US FDA’s Inner Circle Takes Shape: Shah Seen As Potential Successor To Abernethy

Anand Shah returns to FDA as deputy commissioner; like Abernethy, he is an oncologist with a background in big data.

Stephen Hahn Takes US FDA Helm Under Cloud Of Doubt About Vaping Stance

HELP Committee ranking member Patty Murray said because of Hahn's evasive responses to questions about curbing youth e-cigarette use during committee meeeting, she would oppose his confirmation. She also said she was not convinced Hahn would uphold FDA standards.

New US FDA Commissioner Stephen Hahn Heads to White Oak Under Vaping Cloud

Bipartisan Senate confirmation vote comes despite concerns about Stephen Hahn's non-answers to e-cigarette regulation questions.

Related Content

Topics

UsernamePublicRestriction

Register

PS120605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel